Studienzentrum Dr. Bischof GmbH

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)	CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis	Active, not recruiting	Phase 3	2026-09-22	NCT06700343
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)	Relapsing Multiple Sclerosis	Active, not recruiting	Phase 3	2026-09-21	NCT04586010
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Multiple Sclerosis, Primary Progressive, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Active, not recruiting	Phase 3	2026-09-17	NCT04544449

Clinical trials